Primary myelofibrosis Pipeline constitutes 50+ key companies continuously working towards developing 55+ primary myelofibrosis treatment therapies, analyzes DelveInsight

 

DelveInsight’s “Primary Myelofibrosis Pipeline Insight – 2023”  report provides comprehensive global coverage of available, marketed, and pipeline primary myelofibrosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the primary myelofibrosis pipeline domain.

 

Key Takeaways from the Primary Myelofibrosis Pipeline Report

• DelveInsight’s primary myelofibrosis pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for primary myelofibrosis treatment.
• Key primary myelofibrosis companies such as Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences,  Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others are evaluating new drugs for primary myelofibrosis to improve the treatment landscape.
• Promising primary myelofibrosis pipeline therapies in various stages of development include NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat,  KER-050, GB 2064, TL-895,  TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225,  DISC-0974,  BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744,  JAB-8263, Tasquinimod, Mivebresib, 9-ING-41,  Itacitinib, PU-H-71, Selinexor, and others.
• In June 2022, Cellenkos announced that the US Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application to initiate a Phase Ib, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.
• In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis.
• In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.
• In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes.
• In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis.

 

Request a sample and discover the recent advances in primary myelofibrosis treatment drugs @ Primary Myelofibrosis Pipeline Report

 

The primary myelofibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage primary myelofibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the primary myelofibrosis clinical trial landscape.

 

Primary Myelofibrosis Overview

Primary myelofibrosis is a disorder in which normal bone marrow tissue is gradually replaced by fibrous scar-like material. Primary myelofibrosis progressive bone marrow failure over time. Under normal circumstances, the bone marrow provides a fine network of fibers for stem cells to divide and grow on.

Feelings of discomfort, pain, or fullness in the upper left side of the abdomen are common symptoms. An enlarged spleen can also pressure the stomach, causing bloating, indigestion, and a loss of appetite. A physical examination that reveals an enlarged spleen, blood tests, and a bone marrow examination are used for primary myelofibrosis diagnosis.

Primary myelofibrosis is generally thought to be an incurable disease, but with primary myelofibrosis treatment, many people can live comfortably and symptom-free for a long time. The disease’s natural course can vary significantly between individuals.

 

Find out more about primary myelofibrosis treatment drugs @ Drugs for Primary Myelofibrosis Treatment

 

A snapshot of the Primary Myelofibrosis Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Pelabresib	MorphoSys	Phase III	Bromodomain and extraterminal domain protein inhibitor	Oral
Navitoclax	AbbVie	Phase III	Apoptosis stimulant; Proto-oncogene protein c-bcl-2 inhibitor	Oral
KRT-232	Kartos Therapeutics	Phase II/III	Proto-oncogene protein c mdm2 inhibitor	Oral
NS 018	Nippon Shinyaku	Phase II	Janus kinase-2 inhibitor; Src-Family kinase inhibitor	Oral
GB-2064	Galecto	Phase II	LOXL2 protein inhibitors	Oral
TP 3654	Sumitomo Pharma Oncology	Phase I/II	1 Phosphatidylinositol 3 kinase inhibitor; Proto oncogene proteins c pim 1 inhibitor	Oral
LNK01002	Lynk Pharmaceuticals	Phase I	Protein kinase inhibitor	Oral

 

Learn more about the emerging primary myelofibrosis pipeline therapies @ Primary Myelofibrosis Clinical Trials

 

Primary Myelofibrosis Therapeutics Assessment

The primary myelofibrosis pipeline report proffers an integral view of primary myelofibrosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Primary Myelofibrosis Pipeline Report 

• Coverage: Global 
• Primary Myelofibrosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Primary Myelofibrosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Primary Myelofibrosis Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Primary Myelofibrosis Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule, Antibody
• Primary Myelofibrosis Therapeutics Assessment By Mechanism of Action: Janus kinase-2 inhibitors, Src-Family kinase inhibitors, Proto-oncogene protein c mdm2 inhibitors, 1 Phosphatidylinositol 3 kinase inhibitors, Proto oncogene proteins c pim 1 inhibitors, Bromodomain and extraterminal domain protein inhibitors, TGF-beta superfamily protein inhibitors, Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors, Telomerase inhibitors, Erythropoiesis stimulants; Transforming growth factor beta inhibitors, BRD2 protein inhibitors; BRD3 protein inhibitors; BRD4 protein inhibitors
• Key Primary Myelofibrosis Companies: Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences,  Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others
• Key Primary Myelofibrosis Pipeline Therapies: NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat,  KER-050, GB 2064, TL-895,  TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225,  DISC-0974,  BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744,  JAB-8263, Tasquinimod, Mivebresib, 9-ING-41,  Itacitinib, PU-H-71, Selinexor, and others.

 

Dive deep into rich insights for new drugs for primary myelofibrosis treatment; visit @ Primary Myelofibrosis Medications

 

Table of Contents

1.	Primary Myelofibrosis Pipeline Report Introduction
2.	Primary Myelofibrosis Pipeline Report Executive Summary
3.	Primary Myelofibrosis Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Primary Myelofibrosis Clinical Trial Therapeutics
6.	Primary Myelofibrosis Pipeline: Late Stage Products (Phase III)
6.1	Pelabresib: MorphoSys
7.	Primary Myelofibrosis Pipeline: Mid Stage Products (Phase II)
7.1	NS-018: Nippon Shinyaku
8.	Primary Myelofibrosis Pipeline: Early Stage Products (Phase I)
8.1	TP 3654: Sumitomo Pharma Oncology
10.	Primary Myelofibrosis Pipeline Therapeutics Assessment
11.	Inactive Products in the Primary Myelofibrosis Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Primary Myelofibrosis Companies
14.	Key Products in the Primary Myelofibrosis Pipeline
15.	Primary Myelofibrosis Unmet Needs
16.	Primary Myelofibrosis Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services